Abstract
Hepatocyte nuclear factor 1A (HNF1A) is a transcription factor essential to normal pancreas and liver development and homeostasis. HNF1A has been shown to be upregulated in pancreatic cancer stem cells (CSC), a proposed key driver of pancreatic ductal adenocarcinoma (PDAC), relative to other pancreatic cancer cells. A CSC gene signature consisting of 50 upregulated genes, including HNF1A, was previously identified by a microarray. This signature predicts worse survival compared to HNF1A expression alone. This research aims to establish an HNF1A‐dependent gene signature that could potentially be used as a biomarker for pancreatic cancer. Using quantitative reverse transcriptase PCR, multiple CSC signature genes were shown to respond to HNF1A knockdown and overexpression. Responsive genes varied across cell lines, suggesting a complex pathway significantly affected by HNF1A transcriptional control.Support or Funding InformationThe work was supported by the Pancreatic Cancer Action Network‐AACR Pathway to Leadership Grant (16‐70‐25‐ABEL) and the American Cancer Society Postdoctoral Fellowship (127662‐PF‐15‐033‐01‐DDC) (to EVA) and the Gershenson Pancreatic Cancer Fund (DMS) and SKY Foundation (HC and DMS).This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
